

Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM) Minimal Residual Disease (MRD) clinical trial in collaboration with the University of Athens.

This retrospective study is a key component of Telo's expanding, multi-center MRD validation program and is designed to evaluate the clinical utility of Telo's blood-based TeloView®MRD. The University of Athens collaboration provides access to well-characterized clinical blood samples with retrospectively available patient outcomes and an average of approximately three years of follow-up, along with existing serial Next-Generation Flow ("NGF") MRD results.

The study is intended to assess the prognostic performance of TeloView®MRD in predicting patients' risk of relapse and to compare that performance to NGF, one of the two most widely used MRD assessment approaches in MM (alongside Next-Generation Sequencing, "NGS"). The cohort includes NGF MRD results available in both blood and bone marrow, supporting a robust comparative dataset.

TeloView®MRD is designed to detect disease at high sensitivity in blood, with an expected limit of detection down to 1 in 10^7 (one myeloma cell among 10 million blood cells) across different disease stages. In comparison, NGF can reach 10^6 sensitivity in some centers. In addition to MRD enumeration, TeloView®MRD analyzes the 3D genomic architecture of individual MRD cells, which may provide incremental prognostic insight beyond cell counting alone.

Telo continues to advance its prospective MRD trials with Cleveland Clinic and Jewish General Hospital. The Company also expects to announce additional retrospective collaborative studies in Q1 2026 as it builds a multi-center, large-scale clinical evidence package to support adoption and demonstrate comparative performance versus established MRD assays.

"We are pleased to be working with Prof. Meletios A. Dimopoulos and Prof. Efstathios Kastritis from the National and Kapodistrian University of Athens," said Dr. Sabine Mai, Telo's Co-Founder. "This collaboration is expected to meaningfully strengthen our mission to help redefine MRD-guided clinical practice by bringing more actionable, blood-based insights to physicians and patients."

About MRD Assessment

Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. MRD is defined as the small number of cancer cells that remain in the body after treatment. Stratifying MRD cells as in remission or active provides important actionable information for clinicians. FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032.

About Multiple Myeloma

Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time.

The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as \$150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.

About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

For further information, please contact:

Guido Baechler
Executive Chairman
647-477-9365
info@telodx.com
555 Richmond Street West,
Toronto, ON, Canada, M5V 3B1
www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein,

except as required by applicable securities laws.

To view the source version of this press release, please visit

<https://www.newsfilecorp.com/release/278581>